阿尔茨海默病和脑中风中的神经炎性小体
The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke.
作者信息
Lee Jong-Hoon, Lee Chul Joong, Park Jungwuk, Lee So Jeong, Choi Su-Hee
机构信息
Science and Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
Zein Pain Clinic Seongbuk, Seoul, Republic of Korea.
出版信息
Dement Geriatr Cogn Dis Extra. 2021 Jun 10;11(2):159-167. doi: 10.1159/000516074. eCollection 2021 May-Aug.
AIM/BACKGROUND: This review investigated a patient with Alzheimer's disease (AD) treated with 4,4'-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor.
METHODS
We monitored AD's progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state.
RESULTS
By introducing (D), AD's progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct.
CONCLUSIONS
AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24-55 h in the Seoul Study cohort.
目的/背景：本综述研究了一名接受4,4'-二氨基二苯砜（DDS）治疗的阿尔茨海默病（AD）患者，DDS作为一种神经炎性小体竞争剂。
方法
我们使用一种新的生物标志物，通过数字临床分期（NCS）监测AD的进展。NCS由AD症状以及抗AD（AAD）药物（D）引起的神经精神（NP）症状的存在情况作为生物标志物来确定。我们还在无药物摄入的紧急状态下监测了DDS对中风的作用。
结果
通过引入（D），通过NCS分期监测AD的进展。识别出了AAD的副作用和神经精神症状。在因AAD导致NCS为6期的中风患者中停用了DDS，且病情迅速发展为脑梗死。
结论
AAD偶尔会加重AD和中风。DDS可以缓解轻度认知障碍（MCI）、早期AD和中风。我们在临床上证实了DDS在中风后作为神经炎性小体竞争剂的作用。在首尔研究队列中，DDS在24 - 55小时内维持了神经元存活。
Zotero 插件